PortalPublikationenEffect of Chemotherapy on Overall Survival in Contemporary M...

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients

Standard

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. / Hoeh, Benedikt; Würnschimmel, Christoph; Flammia, Rocco S; Horlemann, Benedikt; Sorce, Gabriele; Chierigo, Francesco; Tian, Zhe; Saad, Fred; Graefen, Markus; Gallucci, Michele; Briganti, Alberto; Terrone, Carlo; Shariat, Shahrokh F; Tilki, Derya; Kluth, Luis A; Mandel, Philipp; Chun, Felix K H; Karakiewicz, Pierre I.

in: FRONT ONCOL, Jahrgang 11, 778858, 2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hoeh, B, Würnschimmel, C, Flammia, RS, Horlemann, B, Sorce, G, Chierigo, F, Tian, Z, Saad, F, Graefen, M, Gallucci, M, Briganti, A, Terrone, C, Shariat, SF, Tilki, D, Kluth, LA, Mandel, P, Chun, FKH & Karakiewicz, PI 2021, 'Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients', FRONT ONCOL, Jg. 11, 778858. https://doi.org/10.3389/fonc.2021.778858

APA

Hoeh, B., Würnschimmel, C., Flammia, R. S., Horlemann, B., Sorce, G., Chierigo, F., Tian, Z., Saad, F., Graefen, M., Gallucci, M., Briganti, A., Terrone, C., Shariat, S. F., Tilki, D., Kluth, L. A., Mandel, P., Chun, F. K. H., & Karakiewicz, P. I. (2021). Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. FRONT ONCOL, 11, [778858]. https://doi.org/10.3389/fonc.2021.778858

Vancouver

Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F et al. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. FRONT ONCOL. 2021;11. 778858. https://doi.org/10.3389/fonc.2021.778858

Bibtex

@article{dc13fba1dd9e406b96067d1d98919aa3,
title = "Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients",
abstract = "Introduction: Randomized clinical trials demonstrated improved overall survival in chemotherapy exposed metastatic prostate cancer patients. However, real-world data validating this effect with large scale epidemiological data sets are scarce and might not agree with trials. We tested this hypothesis.Materials and Methods: We identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results (SEER) database (2014-2015). Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed patients vs chemotherapy-na{\"i}ve patients. All analyses were repeated in propensity-score matched cohorts. Additionally, landmark analyses were applied to account for potential immortal time bias.Results: Overall, 4295 de novo metastatic prostate cancer patients were identified. Of those, 905 (21.1%) patients received chemotherapy vs 3390 (78.9%) did not. Median overall survival was not reached at 30 months follow-up. Chemotherapy-exposed patients exhibited significantly better overall survival (61.6 vs 54.3%, multivariable HR:0.82, CI: 0.72-0.96, p=0.01) at 30 months compared to their chemotherapy-na{\"i}ve counterparts. These findings were confirmed in propensity score matched analyses (multivariable HR: 0.77, CI:0.66-0.90, p<0.001). Results remained unchanged after landmark analyses were applied in propensity score matched population.Conclusions: In this contemporary real-world population-based cohort, chemotherapy for metastatic prostate cancer patients was associated with better overall survival. However, the magnitude of overall survival benefit was not comparable to phase 3 trials.",
author = "Benedikt Hoeh and Christoph W{\"u}rnschimmel and Flammia, {Rocco S} and Benedikt Horlemann and Gabriele Sorce and Francesco Chierigo and Zhe Tian and Fred Saad and Markus Graefen and Michele Gallucci and Alberto Briganti and Carlo Terrone and Shariat, {Shahrokh F} and Derya Tilki and Kluth, {Luis A} and Philipp Mandel and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2021 Hoeh, W{\"u}rnschimmel, Flammia, Horlemann, Sorce, Chierigo, Tian, Saad, Graefen, Gallucci, Briganti, Terrone, Shariat, Tilki, Kluth, Mandel, Chun and Karakiewicz.",
year = "2021",
doi = "10.3389/fonc.2021.778858",
language = "English",
volume = "11",
journal = "FRONT ONCOL",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients

AU - Hoeh, Benedikt

AU - Würnschimmel, Christoph

AU - Flammia, Rocco S

AU - Horlemann, Benedikt

AU - Sorce, Gabriele

AU - Chierigo, Francesco

AU - Tian, Zhe

AU - Saad, Fred

AU - Graefen, Markus

AU - Gallucci, Michele

AU - Briganti, Alberto

AU - Terrone, Carlo

AU - Shariat, Shahrokh F

AU - Tilki, Derya

AU - Kluth, Luis A

AU - Mandel, Philipp

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

N1 - Copyright © 2021 Hoeh, Würnschimmel, Flammia, Horlemann, Sorce, Chierigo, Tian, Saad, Graefen, Gallucci, Briganti, Terrone, Shariat, Tilki, Kluth, Mandel, Chun and Karakiewicz.

PY - 2021

Y1 - 2021

N2 - Introduction: Randomized clinical trials demonstrated improved overall survival in chemotherapy exposed metastatic prostate cancer patients. However, real-world data validating this effect with large scale epidemiological data sets are scarce and might not agree with trials. We tested this hypothesis.Materials and Methods: We identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results (SEER) database (2014-2015). Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed patients vs chemotherapy-naïve patients. All analyses were repeated in propensity-score matched cohorts. Additionally, landmark analyses were applied to account for potential immortal time bias.Results: Overall, 4295 de novo metastatic prostate cancer patients were identified. Of those, 905 (21.1%) patients received chemotherapy vs 3390 (78.9%) did not. Median overall survival was not reached at 30 months follow-up. Chemotherapy-exposed patients exhibited significantly better overall survival (61.6 vs 54.3%, multivariable HR:0.82, CI: 0.72-0.96, p=0.01) at 30 months compared to their chemotherapy-naïve counterparts. These findings were confirmed in propensity score matched analyses (multivariable HR: 0.77, CI:0.66-0.90, p<0.001). Results remained unchanged after landmark analyses were applied in propensity score matched population.Conclusions: In this contemporary real-world population-based cohort, chemotherapy for metastatic prostate cancer patients was associated with better overall survival. However, the magnitude of overall survival benefit was not comparable to phase 3 trials.

AB - Introduction: Randomized clinical trials demonstrated improved overall survival in chemotherapy exposed metastatic prostate cancer patients. However, real-world data validating this effect with large scale epidemiological data sets are scarce and might not agree with trials. We tested this hypothesis.Materials and Methods: We identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results (SEER) database (2014-2015). Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed patients vs chemotherapy-naïve patients. All analyses were repeated in propensity-score matched cohorts. Additionally, landmark analyses were applied to account for potential immortal time bias.Results: Overall, 4295 de novo metastatic prostate cancer patients were identified. Of those, 905 (21.1%) patients received chemotherapy vs 3390 (78.9%) did not. Median overall survival was not reached at 30 months follow-up. Chemotherapy-exposed patients exhibited significantly better overall survival (61.6 vs 54.3%, multivariable HR:0.82, CI: 0.72-0.96, p=0.01) at 30 months compared to their chemotherapy-naïve counterparts. These findings were confirmed in propensity score matched analyses (multivariable HR: 0.77, CI:0.66-0.90, p<0.001). Results remained unchanged after landmark analyses were applied in propensity score matched population.Conclusions: In this contemporary real-world population-based cohort, chemotherapy for metastatic prostate cancer patients was associated with better overall survival. However, the magnitude of overall survival benefit was not comparable to phase 3 trials.

U2 - 10.3389/fonc.2021.778858

DO - 10.3389/fonc.2021.778858

M3 - SCORING: Journal article

C2 - 34888250

VL - 11

JO - FRONT ONCOL

JF - FRONT ONCOL

SN - 2234-943X

M1 - 778858

ER -